Erythromycin stimulates phasic gastric contractility as assessed with an isovolumetric intragastric balloon pressure measurement.
VIPUN Gastric Monitoring System
erythromycin
gastric motility
medical device
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
16
06
2020
revised:
24
08
2020
accepted:
26
08
2020
pubmed:
8
10
2020
medline:
3
11
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
A novel technique to assess gastric motility by measuring the pressure in a low-volume intragastric balloon was developed to monitor (disordered) motility. We previously showed that this technique allows measuring pharmacologically induced inhibition of motility. In this study, we assessed whether it is possible to measure pharmacologically induced stimulation of gastric motility using 200 mg erythromycin. Erythromycin is a highly effective stimulator of gastric emptying and contractility. After an overnight fast, a nasogastric balloon catheter was introduced in healthy subjects. After inflation with 120 ml of air, the catheter was connected to a pressure sensor. Intraballoon pressure was continuously recorded for 4 h. After a baseline recording of 2 h, 200 mg erythromycin was infused intravenously over 20 min while the recording continued for 2 h. Epigastric symptoms were surveyed on 100-mm visual analogue scales. Motility was quantified from the pressure recording as a gastric balloon motility index. Wilcoxon signed-rank tests were performed. Data are shown as median (interquartile range). Six subjects were enrolled and five completed the procedures (age: 28 (25-29) years, body mass index: 24.0 (23.8-24.5) kg m Gastric motility assessed via pressure measurement in a low-volume intragastric balloon is able to detect pharmacologically stimulated motility in healthy subjects, which further validates this technique.
Sections du résumé
BACKGROUND
A novel technique to assess gastric motility by measuring the pressure in a low-volume intragastric balloon was developed to monitor (disordered) motility. We previously showed that this technique allows measuring pharmacologically induced inhibition of motility. In this study, we assessed whether it is possible to measure pharmacologically induced stimulation of gastric motility using 200 mg erythromycin. Erythromycin is a highly effective stimulator of gastric emptying and contractility.
METHODS
After an overnight fast, a nasogastric balloon catheter was introduced in healthy subjects. After inflation with 120 ml of air, the catheter was connected to a pressure sensor. Intraballoon pressure was continuously recorded for 4 h. After a baseline recording of 2 h, 200 mg erythromycin was infused intravenously over 20 min while the recording continued for 2 h. Epigastric symptoms were surveyed on 100-mm visual analogue scales. Motility was quantified from the pressure recording as a gastric balloon motility index. Wilcoxon signed-rank tests were performed. Data are shown as median (interquartile range).
KEY RESULTS
Six subjects were enrolled and five completed the procedures (age: 28 (25-29) years, body mass index: 24.0 (23.8-24.5) kg m
CONCLUSIONS AND INFERENCES
Gastric motility assessed via pressure measurement in a low-volume intragastric balloon is able to detect pharmacologically stimulated motility in healthy subjects, which further validates this technique.
Substances chimiques
Gastrointestinal Agents
0
Erythromycin
63937KV33D
Banques de données
ClinicalTrials.gov
['NCT04066231']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13991Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res. 2003;52(1):1-30.
Goelen N, de Hoon J, Morales JF, et al. Codeine delays gastric emptying through inhibition of gastric motility as assessed with a novel diagnostic intragastric balloon catheter. Neurogastroenterol Motil. 2020;32(1):e13733.
Broad JMS, Samadi M, Martin JE, Dukes GE, Sanger GJ. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol. 2012;167(4):763-774.
Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut. 1998;43(3):395-400.
Bjornsson ES, Abrahamsson H. Comparison between physiologic and erythromycin-induced interdigestive motility. Scand J Gastroenterol. 1995;30(2):139-145.
Patcharatrakul T, Gonlachanvit S. Technique of functional and motility test: how to perform antroduodenal manometry. J Neurogastroenterol Motil. 2013;19(3):395-404.
Goelen N, Doperé G, Morales J, et al.Enteral nutrition dose- dependently inhibits phasic gastric motility. European Society of Neurogastroenterology and Motility meeting; 2019 September 5-7, 2019; Lisbon.
Kindt S, Dubois D, Van Oudenhove L, et al. Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia. Neurogastroenterol Motil. 2009;21(11):1183-e105.
Singer AJ, Konia N. Comparison of topical anesthetics and vasoconstrictors vs lubricants prior to nasogastric intubation: a randomized, controlled trial. Acad Emerg Med. 1999;6(3):184-190.
Tatsumi H. Enteral tolerance in critically ill patients. J Intensive Care. 2019;7:30.
Chapman M, Fraser R, Vozzo R, et al. Antro-pyloro-duodenal motor responses to gastric and duodenal nutrient in critically ill patients. Gut. 2005;54(10):1384-1390.
Chapman MJ, Deane AM. Gastrointestinal dysfunction relating to the provision of nutrition in the critically ill. Curr Opin Clin Nutr Metab Care. 2015;18(2):207-212.
Deane AM, Chapman MJ, Reintam Blaser A, McClave SA, Emmanuel A. Pathophysiology and treatment of gastrointestinal motility disorders in the acutely Ill. Nutr Clin Pract. 2019;34(1):23-36.
Ritz MA, Chapman MJ, Fraser RJ, et al. Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill. Intensive Care Med. 2005;31(7):949-954.
Chapman MJ, Deane AM, O'Connor SL, et al. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016;20(1):232.
Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil. 2010;16(4):407-413.
Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55(3):675-683.
Thor P, Lorens K, Tabor S, et al. Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia. J Physiol Pharmacol. 1996;47(3):469-476.
Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut. 2005;54(4):455-460.
Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin - Preliminary studies. N Engl J Med. 1990;322(15):1028-1031.
Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102(3):823-828.
Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Primers. 2018;4(1):41.
Tack J, Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol. 2018;43:111-117.
Tack J, Deloose E, Ang D, et al. Motilin-induced gastric contractions signal hunger in man. Gut. 2016;65(2):214-224.
Chapman MJ, Fraser RJ, Kluger MT, Buist MD, De Nichilo DJ. Erythromycin improves gastric emptying in critically ill patients intolerant of nasogastric feeding. Crit Care Med. 2000;28(7):2334-2337.
Ramirez B, Eaker EY, Drane WE, Hocking MP, Sninsky CA. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci. 1994;39(11):2295-2300.
Petrakis IE, Vrachassotakis N, Vassilakis SJ, Sciacca V, Chalkiadakis G. Erythromycin enhances solid-phase gastric emptying in induced-hyperglycemia in patients with truncal vagotomy and pyloroplasty. Dig Dis Sci. 2000;45(5):937-945.
Burt M, Scott A, Williard WC, et al. Erythromycin stimulates gastric emptying after esophagectomy with gastric replacement: a randomized clinical trial. J Thorac Cardiovasc Surg. 1996;111(3):649-654.
Maes BD, Hiele MI, Geypens BJ, et al. Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline. Gut. 1994;35(3):333-337.